Entecavir

Generic Name
Entecavir
Brand Names
Baraclude, Entecavir Viatris (previously Entecavir Mylan), Entecavir Accord
Drug Type
Small Molecule
Chemical Formula
C12H15N5O3
CAS Number
142217-69-4
Unique Ingredient Identifier
NNU2O4609D
Background

Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS).
...

Indication

For the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.

Associated Conditions
Chronic Hepatitis B Infection
Associated Therapies
-
Clinical Trials
Related News

Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy

First Posted Date
2022-08-10
Last Posted Date
2022-12-27
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
90
Registration Number
NCT05494528
Locations
🇨🇳

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan

🇨🇳

China Medical University Hospital, Taichung, Taiwan

🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

and more 2 locations

Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody)

First Posted Date
2022-07-12
Last Posted Date
2024-05-07
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
84
Registration Number
NCT05453435
Locations
🇨🇳

Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University, Guangzhou, State..., China

The Renal Safety of Tenofovir Alafenamide in HBV-related Acute-on-chronic Liver Failure: Real-World Study

Not Applicable
Completed
Conditions
Antiviral Drugs
Interventions
Drug: Entecavir
Drug: tenofovir alafenamide
First Posted Date
2022-07-12
Last Posted Date
2022-07-12
Lead Sponsor
Xiangya Hospital of Central South University
Target Recruit Count
272
Registration Number
NCT05453448
Locations
🇨🇳

Wenting Peng, Changsha, China

Chronic Kidney Disease Progression in Chronic Hepatitis B Patients on Tenofovir Alafenamide (TAF) Versus Entecavir

Active, not recruiting
Conditions
Chronic Hepatitis B
Interventions
Drug: Entecavir
Drug: Tenofovir alafenamide
First Posted Date
2022-06-21
Last Posted Date
2023-02-08
Lead Sponsor
Chinese University of Hong Kong
Target Recruit Count
1800
Registration Number
NCT05423834
Locations
🇭🇰

Prince of Wales Hospital, Shatin, Hong Kong

Antiviral Therapy for Patients With Chronic Hepatitis B Infection

First Posted Date
2022-05-19
Last Posted Date
2022-05-19
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
238
Registration Number
NCT05382351
Locations
🇨🇳

The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants

First Posted Date
2022-03-11
Last Posted Date
2024-12-06
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
37
Registration Number
NCT05275023
Locations
🇪🇸

Hosp. Univ. Pta. de Hierro Majadahonda, Madrid, Spain

🇬🇧

Imperial College London and Imperial College Healthcare NHS Trust, London, United Kingdom

🇫🇷

Hopital Beaujon, Clichy, France

and more 23 locations

Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV

First Posted Date
2021-11-04
Last Posted Date
2024-04-04
Lead Sponsor
Ascletis Pharmaceuticals Co., Ltd.
Target Recruit Count
43
Registration Number
NCT05107778
Locations
🇨🇳

NanFang Hospital of Southern Medical University, Guangzhou, Guangdong, China

A Single and Repeated Dose Escalation of RBD1016 in Subjects with Chronic Hepatitis B Virus (HBV) Infection

First Posted Date
2021-08-23
Last Posted Date
2024-12-06
Lead Sponsor
Suzhou Ribo Life Science Co. Ltd.
Target Recruit Count
40
Registration Number
NCT05017116
Locations
🇨🇳

The University of Hong Kong, Hong Kong, China

Prophylactic Entecavir for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation

First Posted Date
2021-06-29
Last Posted Date
2022-12-19
Lead Sponsor
Dong-Gun Lee
Target Recruit Count
164
Registration Number
NCT04942886
Locations
🇰🇷

Jeong Won Jang, Seoul, Korea, Republic of

Entecavir and Tenofovir Versus Entecavir in Lymphoma Patients With Positive HBV DNA

Phase 3
Recruiting
Conditions
B-cell Lymphoma
HBV
Interventions
Drug: Entecavir
Drug: Tenofovir
First Posted Date
2020-09-04
Last Posted Date
2020-09-04
Lead Sponsor
Ruijin Hospital
Target Recruit Count
120
Registration Number
NCT04539119
Locations
🇨🇳

Shanghai Ruijin Hospital, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy